Immuneering Corp Class A IMRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMRX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.53
- Day Range
- $1.51–1.63
- 52-Week Range
- $1.38–11.92
- Bid/Ask
- $1.53 / $1.61
- Market Cap
- $46.26 Mil
- Volume/Avg
- 704 / 755,351
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 68
- Website
- https://www.immuneering.com
Comparables
Valuation
|
Metric
|
IMRX
|
ARVN
|
RCKT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.49 | 3.34 | 4.18 |
Price/Sales | — | 22.93 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
IMRX
ARVN
RCKT
Financial Strength
|
Metric
|
IMRX
|
ARVN
|
RCKT
|
|---|---|---|---|
Quick Ratio | 10.92 | 4.93 | 7.69 |
Current Ratio | 11.35 | 4.98 | 7.80 |
Interest Coverage | — | — | −138.48 |
Quick Ratio
IMRX
ARVN
RCKT
Profitability
|
Metric
|
IMRX
|
ARVN
|
RCKT
|
|---|---|---|---|
Return on Assets (Normalized) | −41.41% | −26.31% | −38.11% |
Return on Equity (Normalized) | −45.74% | −58.35% | −43.04% |
Return on Invested Capital (Normalized) | −47.11% | −63.59% | −43.72% |
Return on Assets
IMRX
ARVN
RCKT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Svgmdhsyg | Lxb | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hbqrgxtc | Gklmztf | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bwdlwxz | Pyqqld | $103.3 Bil | |
MRNA
| Moderna Inc | Wkxxvfl | Wpks | $48.1 Bil | |
ARGX
| argenx SE ADR | Gszxyyfhk | Cgqw | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Xczczxdny | Dpt | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hqzhwtq | Bcmzgt | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kzkfpzfgy | Ttcdgzz | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qfdvzrlnvv | Gzszmy | $12.7 Bil | |
INCY
| Incyte Corp | Rrrntcpd | Vmtnjbr | $11.9 Bil |